Physician profile
Edward M Hoffman
NPI 1154313229
$6,008.11
in general payments reported to CMS, 2019-2025
40 companies · $1,471 in 2025
The $1,471 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $802 · 2020: $391 · 2021: $375 · 2022: $613 · 2023: $1,202 · 2024: $1,154 · 2025: $1,471.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,703 · Long Term Medical Supply Or Device Loan: $124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,702.86 |
| Long Term Medical Supply Or Device Loan | $123.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,307.68 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $813.27 | 2021-2025 | |
| Pfizer INC. | $489.74 | 2019-2025 | |
| Lilly USA, LLC | $378.01 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $347.31 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $260.27 | 2019-2025 | Jardiance, Ofev |
| Novartis Pharmaceuticals Corporation | $256.54 | 2021-2025 | |
| Amgen INC. | $246.75 | 2019-2025 | Repatha, Otezla, Evenity |
| Astellas Pharma US INC | $222.08 | 2019-2025 | Veozah |
| Glaxosmithkline, LLC. | $174.63 | 2021-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Dexcom, INC. | $156.80 | 2021-2025 | Dexcom G6 Transmitter |
| Esperion Therapeutics, INC. | $156.13 | 2020-2025 | Nexletol |
| Idorsia Pharmaceuticals US INC | $131.03 | 2022-2024 | Quviviq |
| Baxter Healthcare | $123.96 | 2025 | Hillrom - Spot Vision Screener |
| Paratek Pharmaceuticals, INC. | $117.93 | 2022-2024 | Nuzyra |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Hoffman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.